35 results on '"Rodríguez, Benigno"'
Search Results
2. HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211
3. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy
4. Reply to Barrett, et al
5. CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
6. Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial
7. Prevention of Vaginal SHIV Transmission in Rhesus Macaques through Inhibition of CCR5
8. Current Practices of Screening for Incident Hepatitis C Virus (HCV) Infection Among HIV-Infected, HCV-Uninfected Individuals in Primary Care
9. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection
10. Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment
11. Inflammatory Cytokines Drive CD4⁺ T-Cell Cycling and Impaired Responsiveness to Interleukin 7: Implications for Immune Failure in HIV Disease
12. Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort
13. HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy
14. Natural Cytotoxicity Receptor-Dependent Natural Killer Cytolytic Activity Directed at Hepatitis C Virus (HCV) Is Associated With Liver Inflammation, African American Race, IL28B Genotype, and Response to Pegylated Interferon/Ribavirin Therapy in Chronic HCV Infection
15. Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy
16. Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009
17. Characterizing HIV Transmission Networks Across the United States
18. Baseline Levels of Soluble CD14 and CD16⁺56⁻ Natural Killer Cells Are Negatively Associated With Response to Interferon/Ribavirin Therapy During HCV-HIV-1 Coinfection
19. Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
20. Genetically Associated CD16⁺56⁻ Natural Killer Cell Interferon (IFN)-αR Expression Regulates Signaling and Is Implicated in IFN-α-Induced Hepatitis C Virus Decline
21. Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells
22. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening
23. Chemokine (C-C Motif) Receptor 5 — 2459 Genotype in Patients Receiving Highly Active Antiretroviral Therapy: Race-Specific Influence on Virologic Success
24. Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection
25. Determinants of Protection among HIV-Exposed Seronegative Persons: An Overview
26. Pretreatment Levels of Soluble Cellular Receptors and Interleukin-6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy
27. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada
28. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy–Experienced Patients with HIV Infection in North America
29. Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection
30. Incomplete Peripheral CD4⁺ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment
31. Incomplete Reconstitutìon of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384
32. Cyclosporin a Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy. Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
33. HIV Coinfection Impairs CD28-Mediated Costimulation of Hepatitis C Virus-Specific CD8 Cells
34. Peripheral S-Phase T Cells in HIV Disease Have a Central Memory Phenotype and Rarely Have Evidence of Recent T Cell Receptor Engagement
35. Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus-Infected Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.